SCHEMBL873641

SCHEMBL873641

CCCc1ccc(OCCOC)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
USP2 O75604 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SLCO1B3 Q9NPD5 1/20 0.49
SLCO1B1 Q9Y6L6 1/20 0.49
NPC1 O15118 1/20 0.48
HRH3 Q9Y5N1 2/20 0.47
KDM4E B2RXH2 1/20 0.45
RECQL P46063 1/20 0.45
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27937179 0.98 ALDH1A1 (0.53) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL9509363 0.91 ACACB (0.52) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL14926396 0.90 ALDH1A1 (0.53) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL14926397 0.90 ALDH1A1 (0.53) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL14926398 0.89 ALDH1A1 (0.51) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL19003536 0.89 LMNA (0.58) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL14926400 0.89 ALDH1A1 (0.51) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL29126910 0.88 ALDH1A1 (0.54) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL15581258 0.85 CYP3A4 (0.50) ALDH1A1LMNAL3MBTL1KMT2AMEN1
SCHEMBL9610966 0.85 ALDH1A1 (0.68) ALDH1A1LMNAKMT2AMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US disclosed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 WO disclosed
US-10738242-B2 Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element DIC CORPORATION (JP) 2020-08-11 US disclosed
WO-2020045974-A1 HIGHLY REFRACTIVE EPISULFIDE-BASED OPTICAL MATERIAL STABILIZER, OPTICAL MATERIAL COMPOSITION USING SAME, AND METHOD FOR PRODUCING OPTICAL MATERIAL 주식회사 케이오씨솔루션 2020-03-05 WO disclosed
WO-2020045938-A1 HIGHLY REFRACTIVE EPISULFIDE-BASED OPTICAL MATERIAL STABILIZER, OPTICAL MATERIAL COMPOSITION USING SAME, AND METHOD FOR PRODUCING OPTICAL MATERIAL 주식회사 케이오씨솔루션 2020-03-05 WO disclosed
WO-2020046005-A1 HIGHLY REFRACTIVE EPISULFIDE-BASED OPTICAL MATERIAL STABILIZER, OPTICAL MATERIAL COMPOSITION USING SAME, AND METHOD FOR PRODUCING OPTICAL MATERIAL 주식회사 케이오씨솔루션 2020-03-05 WO disclosed
WO-2020040485-A1 STABILIZER FOR EPISULFIDE-BASED OPTICAL MATERIAL HAVING HIGH REFRACTIVE INDEX, COMPOSITION FOR OPTICAL MATERIAL USING SAME, AND METHOD FOR PRODUCING OPTICAL MATERIAL 주식회사 케이오씨솔루션 2020-02-27 WO disclosed
WO-2020040486-A1 STABILIZER FOR EPISULFIDE-BASED OPTICAL MATERIAL HAVING HIGH REFRACTIVE INDEX, COMPOSITION FOR OPTICAL MATERIAL USING SAME, AND METHOD FOR PRODUCING OPTICAL MATERIAL 주식회사 케이오씨솔루션 2020-02-27 WO disclosed
US-20140221574-A1 COPOLYMER, AND LIQUID CRYSTAL ALIGNMENT LAYER INCLUDING CURED PRODUCT THEREOF DIC CORPORATION (JP) 2014-08-07 US disclosed
US-20140154428-A1 CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF DIC CORPORATION (JP) 2014-06-05 US disclosed
US-20140154428-A1 CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF DIC CORPORATION (JP) 2014-06-05 US disclosed
EP-2727903-A1 CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING HARDENED PRODUCT OF SAID POLYMER DIC Corporation (JP) 2014-05-07 EP disclosed
US-20140121345-A1 CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF DIC CORPORATION (JP) 2014-05-01 US disclosed
US-20140121345-A1 CINNAMIC ACID DERIVATIVE, POLYMER THEREOF, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING CURED PRODUCT THEREOF DIC CORPORATION (JP) 2014-05-01 US disclosed
EP-2619184-A2 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME The Regents of the University of Michigan (US) 2013-07-31 EP disclosed
US-20130116396-A1 POLYMER FOR USE IN LIQUID CRYSTAL ALIGNMENT LAYER DIC CORPORATION (JP) 2013-05-09 US disclosed
US-20130116396-A1 POLYMER FOR USE IN LIQUID CRYSTAL ALIGNMENT LAYER DIC CORPORATION (JP) 2013-05-09 US disclosed
WO-2012040527-A2 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 ALDH1A1 144/4885LMNA 4129/4885L3MBTL1 1110/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 ALDH1A1 89/4885LMNA 3853/4885L3MBTL1 990/4885
US-20220127266-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 ALDH1A1 144/4885LMNA 4129/4885L3MBTL1 1110/4885
US-10738242-B2 Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element PYM1, ZYX, CRY1 ALDH1A1 2197/4885LMNA 1398/4885L3MBTL1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.